WebMar 19, 2008 · Brinavess Generic Name Vernakalant DrugBank Accession Number DB06217 Background Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. WebMar 14, 2024 · BRINAVESS ® (vernakalant HCl) is an antiarrhythmic drug that acts preferentially in the atria by prolonging atrial refractoriness and slowing impulse conduction in a rate-dependent fashion....
BRINAVESS 20 mg/ml, concentrate for solution for infusion
WebSep 26, 2012 · Brinavess, or vernakalant, is a treatment for a type of heartbeat irregularity called atrial fibrillation. An IV form of the drug is approved in the European Union and Latin America but not in the U.S. Merck was developing an oral version of the drug, but canceled that research in March because of regulatory issues. WebJun 24, 2024 · Brinavess (vernakalant HCl, IV) is an antiarrhythmic drug that acts preferentially in the atria by prolonging atrial refractoriness and slowing impulse conduction in a rate-dependent fashion.... firefox hosts 扩展
Brivaness - European Drugs Reference Encyclopedia
WebDue to an expected increased risk of adverse effects, BRINAVESS infusion is contraindicated within 4 hours of intravenous Class I or III antiarrhythmic drug treatment … WebBrinavess must not be given within 30 days of having acute coronary syndrome (a group of heart problems that include unstable angina and heart attacks). Patients on Brinavess must not be given medicines called ‘class I and III anti- arrhythmics’ intravenously during the four hours before or after their Brinavess infusion . For the full list of WebJan 20, 2024 · Brinavess is indicated in adults for rapid conversion of recent onset atrial fibrillation to sinus rhythm -For non-surgery patients: atrial fibrillation ≤ 7 days duration … firefox hosting